AQST — Aquestive Therapeutics Share Price
0.000.00%
Last trade - 00:00- $450.75m
- $390.91m
- $50.58m
- 28
- 27
- 84
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.64% | ||
| Return on Equity | n/a | ||
| Operating Margin | -27.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 52.61 | 45.85 | 50.83 | 47.68 | 50.58 | 58.01 | 57.76 | -5.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Directors
- Santo Costa NEC (75)
- Keith Kendall PRE (63)
- John Cochran NVC (55)
- Ernest Toth CFO (62)
- Daniel Barber COO (45)
- Lori Braender SVP (65)
- Theresa Wood SVP (58)
- Peter Boyd SVP (55)
- Kenneth Marshall SVP (62)
- Gary Slatko SVP (64)
- A. Mark Schobel CTO (65)
- Gregory Brown IND (67)
- Julie Krop IND (54)
- Nancy Lurker IND (63)
- James Scibetta IND (56)
- Marco Taglietti IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 15th, 2004
- Public Since
- July 25th, 2018
- No. of Shareholders
- 87
- No. of Employees
- 135
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 91,059,760
- Address
- 30 Technology Dr, WARREN, 07059-5166
- Web
- https://aquestive.com/
- Phone
- +1 9089411900
- Auditors
- KPMG LLP
Upcoming Events for AQST
Q4 2024 Aquestive Therapeutics Inc Earnings Release
Similar to AQST
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
Avidity Biosciences
NASDAQ Global Market
FAQ
What is the Aquestive Therapeutics share price?
As of Today at 13:18 UTC, shares in Aquestive Therapeutics are trading at $4.95. This share price information is delayed by 15 minutes.
How has the Aquestive Therapeutics share price performed this year?
Shares in Aquestive Therapeutics last closed at $4.95 and the price had moved by +282.24% over the past 365 days. In terms of relative price strength the Aquestive Therapeutics share price has outperformed the S&P500 Index by +186.36% over the past year.
What are the analyst and broker recommendations for Aquestive Therapeutics?
The overall consensus recommendation for Aquestive Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aquestive Therapeutics dividend yield?
Aquestive Therapeutics does not currently pay a dividend.
Does Aquestive Therapeutics pay a dividend?
Aquestive Therapeutics does not currently pay a dividend.
When does Aquestive Therapeutics next pay dividends?
Aquestive Therapeutics does not currently pay a dividend.
How do I buy Aquestive Therapeutics shares?
To buy shares in Aquestive Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aquestive Therapeutics?
As of the previous close price of $4.95, shares in Aquestive Therapeutics had a market capitalisation of $450.75m.
Where are Aquestive Therapeutics shares listed?
Here are the trading details for Aquestive Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AQST
What kind of share is Aquestive Therapeutics?
Based on an overall assessment of its quality, value and momentum Aquestive Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aquestive Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Aquestive Therapeutics is $9.44. That is 90.71% above the last closing price of $4.95.
Analysts covering Aquestive Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
Find out moreWhat is the trend in the Aquestive Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aquestive Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +9.21%.
As of the last closing price of $4.95, shares in Aquestive Therapeutics were trading +41.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aquestive Therapeutics PE Ratio?
The Aquestive Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aquestive Therapeutics?
Aquestive Therapeutics' management team is headed by:
- Santo Costa - NEC
- Keith Kendall - PRE
- John Cochran - NVC
- Ernest Toth - CFO
- Daniel Barber - COO
- Lori Braender - SVP
- Theresa Wood - SVP
- Peter Boyd - SVP
- Kenneth Marshall - SVP
- Gary Slatko - SVP
- A. Mark Schobel - CTO
- Gregory Brown - IND
- Julie Krop - IND
- Nancy Lurker - IND
- James Scibetta - IND
- Marco Taglietti - IND